AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Dec 2016 04:00 PM
RNS
Block listing Interim Review
01 Dec 2016 03:00 PM
RNS
Total Voting Rights
22 Nov 2016 07:00 AM
RNS
AZ head and neck cancer trials resume enrolment
17 Nov 2016 07:00 AM
RNS
AZ out-licensing deal with Allergan completed
10 Nov 2016 07:04 AM
RNS
Year-To-Date and Q3 2016 Results
09 Nov 2016 07:00 AM
RNS
Directorate Change
01 Nov 2016 03:30 PM
RNS
Dealing by Person Closely Associated
01 Nov 2016 03:00 PM
RNS
Total Voting Rights
31 Oct 2016 01:47 PM
RNS
AZ completes US Aralez agreement for Toprol-XL
27 Oct 2016 04:51 PM
RNS
AstraZeneca Head and Neck Cancer Trials
26 Oct 2016 07:00 AM
RNS
Positive results in AstraZeneca Lynparza trial
18 Oct 2016 07:00 AM
RNS
FDA accepts for review ZS-9 NDA for hyperkalaemia
07 Oct 2016 07:00 AM
RNS
AZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US
04 Oct 2016 07:05 AM
RNS
AZ agreement with Aralez for Toprol-XL in US
04 Oct 2016 07:00 AM
RNS
AstraZeneca reports top-line EUCLID results in PAD
03 Oct 2016 03:00 PM
RNS
Total Voting Rights
03 Oct 2016 07:00 AM
RNS
MedImmune out-licenses medicine to Allergan
28 Sep 2016 07:00 AM
RNS
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
26 Sep 2016 04:00 PM
RNS
Director/PDMR Shareholding
22 Sep 2016 11:00 AM
RNS
Director Declaration
01 Sep 2016 02:30 PM
RNS
Total Voting Rights
01 Sep 2016 07:00 AM
RNS
AstraZeneca Completes Aspen Agreement
24 Aug 2016 07:00 AM
RNS
AZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
18 Aug 2016 01:00 PM
RNS
Director Declaration
16 Aug 2016 07:00 AM
RNS
AstraZeneca completes agreement with LEO Pharma
10 Aug 2016 02:41 PM
RNS
ASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
09 Aug 2016 07:00 AM
RNS
ASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
01 Aug 2016 02:30 PM
RNS
Total Voting Rights
01 Aug 2016 11:00 AM
RNS
Director/PDMR Shareholding
28 Jul 2016 07:00 AM
RNS
AZN: H1 2016 Results
27 Jul 2016 09:00 AM
RNS
Notice of Results
19 Jul 2016 02:15 PM
RNS
QTERN (saxa/dapa) EU approved for type-2 diabetes
18 Jul 2016 07:00 AM
RNS
TAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL
14 Jul 2016 12:07 PM
RNS
Second Price Monitoring Extn
14 Jul 2016 12:02 PM
RNS
Price Monitoring Extension
13 Jul 2016 07:00 AM
RNS
AZ resolves Faslodex patent litigation in the US
01 Jul 2016 05:30 PM
RNS
Total Voting Rights
01 Jul 2016 07:00 AM
RNS
AZ enters licensing agreements with LEO Pharma
28 Jun 2016 07:00 AM
RNS
Zavicefta approved in EU
23 Jun 2016 07:00 AM
RNS
AstraZeneca updates on Flumist vaccine in the US
14 Jun 2016 03:00 PM
RNS
Director/PDMR Shareholding
09 Jun 2016 07:03 AM
RNS
AZ agreement with Aspen for anaesthetics portfolio
03 Jun 2016 07:00 AM
RNS
AZ completes US licensing agreement with Ironwood
02 Jun 2016 07:00 AM
RNS
AZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH
01 Jun 2016 12:00 PM
RNS
Block listing Interim Review
01 Jun 2016 11:30 AM
RNS
Total Voting Rights
27 May 2016 12:36 PM
RNS
POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
27 May 2016 07:03 AM
RNS
Positive results from AstraZeneca Faslodex trial
27 May 2016 07:00 AM
RNS
AstraZeneca receives CRL from US FDA for ZS-9
23 May 2016 04:00 PM
RNS
Director/PDMR Shareholding

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings